ReviewCancer immunology, immunotherapy : CII2014
Foxp3 expression in T regulatory cells and other cell lineages.
Review in Cancer immunology, immunotherapy : CII, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- The Prognostic Value of Forkhead Box P3 Expression in Operable Breast Cancer: A Large-Scale Meta-Analysis.PloS one · 2015Pooled it
- Haplotypes of FOXP3 genetic variants are associated with susceptibility, autoantibodies, and TGF-β1 in patients with systemic lupus erythematosus.Scientific reports · 2021Trial
- Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis.Arthritis research & therapy · 2017Trial
- First Comprehensive Analysis of Full-Length and Δ2 Foxp3 Isoforms Distribution in PBMCs from Healthy Volunteers.Biomolecules · 2026Article
- High-Throughput Phenotypic Screen to Identify FoxP3 Regulators in Primary T Cells.ACS chemical biology · 2026Article
- FoxP3+ Cells and PNAd+ Tumour-Associated High Endothelial Venules: Synergistic Prognostic Markers in Oral Tongue Squamous Cell Carcinoma.Head and neck pathology · 2026Article
- The likely possibility of predicting treatment outcomes of cervical lesions using serum FOXP3 and P16INK4A as shown by a cohort study in South Western Uganda.Discover oncology · 2026Article
- Taming autoimmune thyroiditis: cellular immunomodulation through MSCs, Tregs, and tolDCs.Frontiers in immunology · 2026Review
- Experimental autoimmune encephalomyelitis impairs the immunomodulatory effects of mesenchymal stem cells on splenocyte responses.Molecular biology reports · 2025Article
- Carcinogenic and anticancer activities of microbiota-derived secondary bile acids.Frontiers in oncology · 2025Review
- Immunogenic Switch of RPE Cells.Advances in experimental medicine and biology · 2025Review
- Tumor Resection in Hepatic Carcinomas Restores Circulating T Regulatory Cells.Journal of clinical medicine · 2024Article
- Expression and Prognostic Significance of LAG-3, TIGIT, VISTA, and IDO1 in Endometrial Serous Carcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024Article
- Review
- Quantification of CD3, FoxP3, and granzyme B immunostaining in canine renal cell carcinoma.Veterinary immunology and immunopathology · 2024Article
- Quantitative performance assessment of Ultivue multiplex panels in formalin-fixed, paraffin-embedded human and murine tumor specimens.Scientific reports · 2024Article
- Review
- Intragraft regulatory T cells in the modern era: what can high-dimensional methods tell us about pathways to allograft acceptance?Frontiers in immunology · 2023Review
- Inhibition of FOXP3 by stapled alpha-helical peptides dampens regulatory T cell function.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Forkhead box P3 (Foxp3) is an important transcription factor that belongs to the forkhead/winged-helix family of transcriptional regulators. Foxp3 has been extensively studied over the past 13 years as a master regulator of transcription in a specific T-cell type, CD4(+) regulatory T cells (Treg), both in humans and in mice. Compelling data characterize Foxp3 as critically important and necessary for the development and the differentiation of Treg. It has been considered initially as the only specific marker for Treg. However, recent work has proposed that Foxp3 can be expressed by other types of lymphoid cells or myeloid cells and also by some non-hematopoietic cells such as epithelial cells. It remains controversial about the expression of Foxp3 in cells other than Treg, but understanding the potential expression and function of this master regulator in different cell subsets could have a wide range of implications for immune tolerance and several pathologies including autoimmune disorders and immune responses to cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.